- Virbac’s third-quarter revenue in 2024 reached €339.2 million, marking a 7.8% increase from the previous year’s €314.8 million.
- When considering organic revenue at constant exchange rates and scope, the growth was 3.4%.
- The third-quarter performance was influenced by an unfavorable base effect, as 2023 experienced a recovery in activity after two significant challenges: limited production capacity for vaccines and a cyberattack in June 2023.
- The company reaffirms its outlook for 2024, expecting revenue growth between 7% and 9% at constant exchange rates and scope.
- The adjusted EBIT ratio is projected to be around 16%.
- Virbac has recently acquired Globion in India and Sasaeah in Japan, reflecting strategic expansion efforts.
- Market sentiment towards Virbac shows a strong inclination towards buying, with 7 buy ratings, 4 hold ratings, and no sell ratings.
A look at Virbac SA Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 2 | |
| Growth | 4 | |
| Resilience | 4 | |
| Momentum | 5 | |
| OVERALL SMART SCORE | 3.4 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Virbac SA, a company specializing in manufacturing antibiotics, worm medicines, and vaccines for veterinary use, has received a mixed bag of Smart Scores indicating its long-term outlook. With a Growth score of 4 and a Resilience score of 4, Virbac SA demonstrates a promising potential for future expansion and a strong ability to weather economic uncertainties. In addition, the company’s Momentum score of 5 suggests a positive trend in its stock performance, hinting at potential upward movement.
However, Virbac SA falls short in the Value and Dividend categories, both scoring a 2, which may raise concerns for investors looking for strong fundamental indicators. Despite this, the company’s core focus on veterinary pharmaceuticals and its global distribution network across key regions like the United States, Europe, Asia, and South America provide a solid foundation for continued growth and market presence.
Summary: Virbac SA manufactures antibiotics, worm medicines, and vaccines for veterinary use. The Company’s products are distributed in the United States, Europe, Asia, and South America.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
